Exploring the Fecal Microbiome Dysbiosis and Its Plasma Metabolome Determinants in Advanced Parkinson's Disease With Motor Complications.

PD-MC patients exhibited distinct gut microbial signatures compared to PD without motor complications patients.

• Study enrolled 108 PD patients for 16S rRNA gut microbiome profiling.
• PD-MC patients showed increased fecal abundance of Lactobacillus, Limosilactobacillus, Bifidobacterium, and Ligilactobacillus genera.
• PD-MC patients showed depleted Agathobacter compared to PD-NMC individuals.
• Gut microbiome profiling was performed using 16S rRNA sequencing methodology.

PD-MC patients had distinct plasma metabolomic profiles compared to PD-NMC patients.

• 246 PD patients underwent plasma nontargeted metabolomics analysis.
• Differential plasma metabolites identified included 3-deoxysappanchalcone (3-DSC), 1,3-Dimethyluracil (1,3-DTl), Leucine, and N-Acetylisoleucine (N-AIL), Dodec-6-enoic acid (D-6-E), N-butyl Oleate (N-BO), and 4-hydroxyundecanoic acid (4-HUA).
• Functional interpretation of key metabolites was conducted through enrichment and pathway analysis using KEGG and SMPDB databases.

Fecal microbiota aberrations in PD-MC patients were linked to plasma metabolic changes.

• Spearman correlation analysis was used to evaluate relationships between differential metabolites and microorganisms.
• Results indicated associations between key microbial populations and metabolomic profiles in PD-MC.
• The correlation analysis connected gut microbiome dysbiosis to specific plasma metabolite alterations in the PD-MC context.

A multivariate diagnostic model for PD-MC was developed using discriminative gut microbial and plasma metabolite features.

• The diagnostic model utilized both gut microbiota signatures and plasma metabolites as discriminative features.
• The model was developed in the context of 108 patients for microbiome and 246 patients for metabolomics profiling.
• The study identified these combined multiomics features as potential diagnostic biomarkers for PD-MC.

Gut microbiota and plasma metabolite perturbations are described as closely associated with the etiopathogenesis of Parkinson's disease.

• PD-MC currently lacks effective diagnostic and therapeutic strategies according to the authors.
• Whether fecal microbiome dysbiosis and changed plasma metabolites are involved in PD progression, particularly in PD-MC development, was previously unclear.
• The study used an extensive multiomics analysis involving both 16S rRNA gut microbiome profiling and plasma nontargeted metabolomics to address this gap.